IL17A and psoriatic arthritis: Secukinumab (SEC) is a recombinant human monoclonal antibody against interleukin-17A (IL17A) that has been approved since 2015 by the European Medicines Agency (EMA) and 2016 by the US Food and Drug Administration (FDA), for the treatment of psoriatic arthritis (PsA) (1, 2).